Association between sarcopenia and risk of major adverse cardiac and cerebrovascular events‐UK Biobank database

Abstract

BackgroundFew studies on the risk of incident major adverse cardiac and cerebrovascular events (MACCEs) in sarcopenia have been reported. The objective was to assess the association between presarcopenia and sarcopenia and a higher risk of MACCEs.MethodsThis study on the UK Biobank prospective cohort, used data collected between 2006 and 2021. Community‐dwelling Caucasian participants aged 37 to 73 years were included if values for Handgrip Strength (HGS) and Skeletal Muscle Index (SMI) were available and if no history of MACCEs was reported. Exposure was assessed using the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria. Muscle strength was measured using HGS, and muscle mass using the SMI. Presarcopenia was defined through the two definitions available in the literature, as low HGS with normal SMI and as normal HGS with low SMI, whereas sarcopenia was defined as low HGS with low SMI. The main outcome was to determine whether presarcopenia and/or sarcopenia were predictors of MACCEs (composite events).ResultsA total of 406,411 included participants (women: 55.7%) were included. At baseline, there were 18,257 (4.7%) presarcopenics—subgroup n°1 (low HGS only), 7940 (2.1%) presarcopenics—subgroup n°2 (low SMI only), and 1124 (0.3%) sarcopenics. Over a median follow‐up of 12.1 years (IQR: [11.4; 12.8]), 28,300 participants (7.0%) were diagnosed with at least one event. Compared to NonSarc, presarcopenic (subgroups n°1 and n°2) and sarcopenic status were significantly associated with a higher risk of MACCEs (respectively fully adjusted HRs: HR = 1.25 [95% CI: 1.19; 1.31], HR = 1.33 [95% CI: 1.23; 1.45] and HR = 1.62 [95% CI: 1.34; 1.95]).ConclusionsIn a community‐dwelling population, the risk of MACCEs was higher in both presarcopenic and sarcopenic participants.

Targeting cardiac and cerebrovascular risks of sarcopenia: Is it time to screen for muscle health?

“…To this end, the article by Jauffret et al in this issue of the journal examines the association of pre-sarcopenia and sarcopenia with the risk of incident major adverse cardiac and cerebrovascular events (MACCEs) in the UK Biobank. 12 The authors utilize the widely used 2018 EWGSOP2 criteria and cutoffs to define sarcopenia as low muscle mass and strength. 1 Pre-sarcopenia, a term not used by EWGSOP2, was defined as either low muscle mass or strength alone.…”